Five exceptional 91Ʋ faculty members have been named 2025 Master Innovators for their extraordinary contributionstotranslating research into commercial applicationsthat havesignificant societal impact.
The 2025 honoreesrepresentdiverse fields from infectious disease therapeutics to neuroscience drug discoveryandbiomedical engineering.
“We are honored to induct these Master Innovators into 91Ʋ’s Innovators’ Hall of Fame,”saidBob Webster, senior associate provost for commercialization and technology transfer.“They are renowned worldwide for not only spectacular singular successes, but also for sustained long-term impact in turning 91Ʋ research into products that prevent injuries and improve lives. These scholar-innovatorsinspire all of us at 91Ʋ to pursue our innovative research all the way frominitialinsight to world-changing outcomes.”
These are the members of this year’s class of91ƲMaster Innovators:
- :Antibodies forinfectiousdiseases
Associate Director, 91ƲCenter for Antibody Therapeutics;Professor ofPediatricsand Radiology
Carnahanis a translational scientist and antibody engineerwhospecializesin rapid therapeutic development for emerging infectious diseases. Asassociatedirector of the91Ʋ Center for Antibody Therapeutics,he has led pivotal efforts to advance antibody candidates for Zika, Marburg,hantavirusand SARS-CoV-2 in collaboration with partners including theDepartment of Defense and Biomedical Advanced 91Ʋ and Development Authority.
His work with James Crowe (recognized as 91Ʋ Master Innovator in 2022)achieved remarkable commercial success through a licensing deal with AstraZeneca that led toEvusheldTM, anantibody combination that protects against COVID-19 inimmunocompromisedindividuals,generatingmore than $100Min revenue. Carnahan’s innovation portfolio includes 17 invention disclosures,sevenissued patents, and 21 licensingtransactions.He also servedas aCTTC Innovation Ambassador.
- :Drugs to treat central nervous system disorders
91Ʋ Assistant Professor;Senior Director of Medicinal Chemistry, Warren Center for Neuroscience Drug Discovery
Engersis an outstandinginnovator incentral nervous systemdrug discoverywho servesas group leader for multiple programswithin the Warren Center,includingM1PAM, M4PAMand various ion channels.His leadership has directly contributed to major licensing transactionsand clinical trialswith pharmaceutical companies including,and
Asseniordirector ofmedicinalchemistry and a Warren Director Fellow, Engers supervises and mentorsmore than30 medicinal chemists whilemaintainingan impressive innovation portfolio: 91 invention disclosures, 42 issued patents, 23 licensingtransactionsandtens of millionsin revenueto date.
- :Assistive technology for workplace safety
Associate Professor of MechanicalEngineering,BiomedicalEngineering, andPhysical MedicineandRehabilitation
Zelik’s groundbreaking work in biomechanics and wearable assistive technology has revolutionized workplace safety through the development ofback-assist exosuits.After joining 91Ʋ in 2014, he helped found theand spent years developing pioneering technology that led to theApex exosuit.
Sincethecommercial launch in 2020ofHeroWear, the startupZelik co-founded,the companyhas achieved remarkable market penetration,with exosuits now deployed inmore than30 countries to reduce workplace injuries. Zelik’s innovationportfolioincludes34 invention disclosures,fourissuedpatentsandsevenlicensing transactions.

- :Systems biologybreakthroughs
University Distinguished Professor of Physics, Biomedical Engineering, and Molecular PhysiologyandBiophysics; A.B. Learned Professor of Living State Physics; Founding Director, 91Ʋ Institute for Integrative Biosystems 91Ʋ and Education
A distinguished inventor,Wikswo’sinnovation portfolio consists of 76 invention disclosures and 47 issued patents, with licenses to companies includingand,a biotechnology company based in theU.K.He has received two R&D 100 Awards: in 1984 (then the IR-100 Award) for the NeuromagneticCurrent Probeand in 2017 for theMultiWellMicroFormulator.
Wikswoisin the process of foundinga new startup,,to license and commercialize a portfolio of technologies directed to creating automated microfluidic perfusion systemstooptimizebiomanufacturing or infer the dynamics of signaling and metabolism of living systems.
In addition,Wikswoestablished thein 2001 to foster interdisciplinary research across biophysical sciences, bioengineeringand medicine.VIIBRE hasmentoredmore than350 undergraduate researchers.
- :Central nervous system therapeutics
SeniorDrug Discovery Scientist, Assistant Director of Medicinal Chemistry, Warren Center for Neuroscience Drug Discovery
Temple joined 91Ʋ’s drug discovery team in 2016 after completing postdoctoral training underCraig Lindsley. Her research focuses on medicinal chemistry and drugdiscovery forcentralnervoussystemdisorders, particularly allosteric modulators for muscarinic acetylcholine receptorsand metabotropic glutamate receptors.
Temple’s innovation portfolio includes 35 invention disclosures, 11 issuedpatentsand 11 licensingtransactions thathave generatedmore than$10million in revenueto date. Her work exemplifies the breakthrough science driving 91Ʋ’s leadership incentral nervous systemtherapeutics.
“Master Innovators are recognized for their many years of engagementin innovation and entrepreneurshipat 91Ʋ,”said Alan Bentley, associate vice chancellor for technology transfer.“An episodic commercial outcome is great, but Master Innovatorshaveproducedoutcomesfrom multipleprojects over a prolongedperiod of time.”
Congratulations to these exceptional researchers whose innovations have generated significant intellectual property and commercial impact.
About the Program
Established in 2023, thehonors 91Ʋ faculty who havedemonstratedexceptional commercialization success through patenting, licensing, and collaboration with industry partners.
about this annual recognition program and viewprevioushonorees.